1,031 results match your criteria Pruritus and Systemic Disease


Progressive Familial Intrahepatic Cholestasis Type 2 and Recurrence After Liver Transplantation: A Case Report.

Transplant Proc 2022 Jun 16. Epub 2022 Jun 16.

Brasília Children's Hospital, Brasilia, Federal District, Brazil.

Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare autosomal recessive disorder caused by mutations in the ABCB11 gene. Clinical manifestations include cholestasis with low γ-glutamyltransferase (GGT), hepatosplenomegaly, and severe pruritus. Liver transplantation is required for individuals with progressive liver disease or failure of the bypass procedure and has been considered curative. Read More

View Article and Full-Text PDF

Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.

Dermatol Ther 2022 Jun 17:e15648. Epub 2022 Jun 17.

Department of Allergy & Immunology, Huashan Hospital affiliated to Fudan University, No 12, Wulumuqi Middle Road, Shanghai, China.

Background: Routine systemic therapy for bullous pemphigoid (BP) has been challenged due to the inevitably adverse effects. According to the successful applications of dupilumab in BP cases reported, therefore, we investigate the real-life efficacy and safety of dupilumab combined with low-dose oral steroid for BP.

Research Design And Methods: A cohort of BP patients who received either dupilumab plus low-dose methylprednisolone (dupilumab group) or merely methylprednisolone (control group) was retrospectively reviewed. Read More

View Article and Full-Text PDF

Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study.

Dermatol Ther (Heidelb) 2022 Jun 11;12(6):1469-1480. Epub 2022 Jun 11.

Sapporo Skin Clinic, Sapporo, Japan.

Introduction: Patients with mild-to-moderate plaque psoriasis often experience reduced quality of life and increased disease burden due to itch or involvement of psoriasis in special areas such as the scalp and nails. Systemic therapy may be used concurrently with topical therapy in patients with active disease not controlled by topical therapy alone. The objective of PROMINENT was to evaluate the efficacy and safety of apremilast in combination with topical therapy in patients with mild-to-moderate psoriasis in Japan. Read More

View Article and Full-Text PDF

Chronic prurigo.

Authors:
Laurent Misery

Br J Dermatol 2022 Jun 3. Epub 2022 Jun 3.

Univ Brest, LIEN, Brest, France.

Chronic prurigo is a distinct disease defined by the presence of chronic pruritus for at least 6 weeks, a history and/or signs of repeated scratching, and multiple localized or generalized pruritic skin lesions (whitish or pinkish papules, nodules and/or plaques). Although chronic prurigo is frequently named prurigo nodularis, the nodular type of chronic prurigo is only the main clinical aspect of chronic prurigo. Chronic prurigo occurs due to neural sensitization to pruritus and the development of a vicious pruritus-scratching cycle. Read More

View Article and Full-Text PDF

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.

Cancer Sci 2022 Jun 2. Epub 2022 Jun 2.

Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Talimogene laherparepvec (T-VEC) is approved for the treatment of unresectable melanoma in the US, Europe, and Australia. This phase I, multicenter, open-label, dose de-escalation study evaluated the safety and efficacy of T-VEC in Japanese patients with unresectable stage IIIB-IV melanoma. Eligible adult patients had histologically confirmed stage IIIB-IVM1c cutaneous melanoma, may have received prior systemic anticancer therapy, must have had ≥ 1 injectable lesion, serum lactate dehydrogenase ≤ 1. Read More

View Article and Full-Text PDF

Management of atopic dermatitis: a narrative review.

Med J Aust 2022 Jun 29;216(11):587-593. Epub 2022 May 29.

Eastern Health, Monash University, Melbourne, VIC.

Atopic dermatitis (atopic eczema) is the most common inflammatory skin disease and has a significant burden on the quality of life of patients, families and caregivers. Its pathogenesis is a complex interplay between genetics and environment, involving impaired skin barrier function, immune dysregulation primarily involving the Th2 inflammatory pathway, itch, and skin microbiome. Restoration of skin barrier integrity with regular emollients and prompt topical anti-inflammatory therapies are mainstays of treatment. Read More

View Article and Full-Text PDF

Probiotics Function in Preventing Atopic Dermatitis in Children.

Int J Mol Sci 2022 May 12;23(10). Epub 2022 May 12.

Pediatric Clinic, Department of Pediatrics, Fondazione IRCSS Policlinico San Matteo, University of Pavia, 27100 Pavia, Italy.

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing eczematous injuries and severe pruritus. In the last few years, the AD prevalence has been increasing, reaching 20% in children and 10% in adults in high-income countries. Recently, the potential role of probiotics in AD prevention has generated considerable interest. Read More

View Article and Full-Text PDF

Uremic Pruritus: From Diagnosis to Treatment.

Diagnostics (Basel) 2022 Apr 28;12(5). Epub 2022 Apr 28.

Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.

Uremic pruritus, or chronic kidney disease-associated pruritus, is common, bothersome, and sometimes debilitating in patients with chronic kidney disease or end-stage renal disease. Due to its variable clinical manifestations, the diagnosis of uremic pruritus requires exquisite evaluation. Excluding itch resulting from other dermatological causes as well as other systemic conditions is essential for a proper diagnosis. Read More

View Article and Full-Text PDF

Psychosocial Burden of Itch among Renal Transplant Recipients.

Toxins (Basel) 2022 04 30;14(5). Epub 2022 Apr 30.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland.

Itch is the most common symptom of chronic dermatoses. Moreover, itch may be associated with systemic disorders. Chronic kidney disease-associated itch (CKD-aI) may affect up to 20% of renal transplant recipients (RTR). Read More

View Article and Full-Text PDF

New Topical Therapies in Development for Atopic Dermatitis.

Drugs 2022 Jun 21;82(8):843-853. Epub 2022 May 21.

Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal.

Atopic dermatitis (AD) is a common chronic pruritic inflammatory cutaneous disease. AD is characterized by intense pruritus and enormous clinical heterogeneity. Treatment goals are to improve skin lesions and minimize exacerbations and symptom burden. Read More

View Article and Full-Text PDF

Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).

Dermatol Ther (Heidelb) 2022 Jun 20;12(6):1417-1430. Epub 2022 May 20.

Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA.

Introduction: Dupilumab was initially approved in 2017 as the first biologic therapy for atopic dermatitis (AD). We characterized adults with AD initiating dupilumab in a real-world setting in the USA/Canada.

Methods: PROSE is an ongoing, longitudinal, prospective, observational, multicenter registry of patients with AD initiating dupilumab per country-specific prescribing information. Read More

View Article and Full-Text PDF

Desire for Alternative Treatment Options in Patients with Atopic Dermatitis in Japan: Results of a Web-Based Cross-Sectional Study (AD-JOIN Study).

Dermatol Ther (Heidelb) 2022 Jun 18;12(6):1383-1396. Epub 2022 May 18.

Medical Department, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo, 108-0023, Japan.

Introduction: Treatment satisfaction in patients with atopic dermatitis (AD) has been investigated in several studies, but the desire for alternative treatment options is unclear and has not been previously evaluated. We conducted a cross-sectional, web-based survey aimed at evaluating the desire for alternative treatment options in adults with AD from a patient registry in Japan.

Methods: Main eligibility criteria were adults aged ≥ 18 years with AD who were receiving treatment with topical corticosteroids (TCS) and not systemic therapy. Read More

View Article and Full-Text PDF

Uremic pruritus: pathophysiology, clinical presentation, and treatments.

Kidney Res Clin Pract 2022 May 4. Epub 2022 May 4.

Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.

Uremic pruritus is one of the most common and bothersome symptoms in patients with end-stage renal disease. Most patients with uremic pruritus experience a prolonged and relapsing course and significant impairments of quality of life. The pathophysiology of uremic pruritus is not completely understood. Read More

View Article and Full-Text PDF

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.

Am J Clin Dermatol 2022 May 3;23(3):393-408. Epub 2022 May 3.

Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA.

Background: Moderate-to-severe atopic dermatitis (AD) often requires long-term management with systemic therapies.

Objective: Our objective was to report the safety and efficacy of dupilumab treatment up to 4 years in adults with moderate-to-severe AD and efficacy in a subgroup of patients who transitioned from dupilumab once-weekly (qw) to administration every other week (q2w).

Methods: This interim analysis of the open-label extension study (NCT01949311) evaluated dupilumab 300 mg qw or q2w in adults previously enrolled in dupilumab trials for moderate-to-severe AD. Read More

View Article and Full-Text PDF

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis.

Authors:
Sheridan M Hoy

Am J Clin Dermatol 2022 May 3;23(3):409-420. Epub 2022 May 3.

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Baricitinib (Olumiant) is an oral small molecule inhibitor of Janus kinase (JAK)1 and JAK2, which have been implicated in the pathogenesis of atopic dermatitis (AD). In phase III studies in adults with moderate to severe AD who were inadequately controlled with topical corticosteroids (TCS) or systemic treatments (e.g. Read More

View Article and Full-Text PDF

Identifying predictors of systemic immunosuppressive treatment of vulvovaginal lichen planus: A retrospective cohort study of 122 women.

Australas J Dermatol 2022 May 2. Epub 2022 May 2.

Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Background: Between 20% and 40% of women with vulvovaginal lichen planus (VLP) fail to respond to first-line ultra-potent topical corticosteroid treatment and require systemic immunosuppression to control disease. No data exist regarding risk factors for patients with severe VLP requiring systemic immunosuppression. We aimed to identify clinical features that predict women with VLP who are at risk of severe, recalcitrant disease requiring eventual escalation to systemic treatment. Read More

View Article and Full-Text PDF

Topical tacrolimus during systemic therapy for severe atopic dermatitis in the clinical practice.

Eur Rev Med Pharmacol Sci 2022 04;26(7):2518-2523

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Objective: To evaluate the role of tacrolimus ointment in the management of patients on dupilumab therapy for severe atopic dermatitis, in a real-life setting.

Patients And Methods: Consecutive patients with severe AD treated with dupilumab were enrolled. Topical treatment was associated according to the clinical practice. Read More

View Article and Full-Text PDF

Adult Onset Still's Disease.

Authors:
Ankur Dalal

J Assoc Physicians India 2022 Mar;70(3):11-12

Consultant Physician and Rheumatologist, Ex- Assistant Professor in Medicine, The Sarvajanik Medical Trust Hospital, Surat, Gujarat.

Adult onset Still's disease (AOSD) is a rare systemic inflammatory disorder of unknown aetiology, characterised by daily spiking high fevers accompanied by rash, arthritis, and systemic manifestations. There are no specific diagnostic tests for AOSD. To establish the diagnosis of AOSD one should require the fulfilment of proposed major and minor criteria as well as exclusion of other diseases. Read More

View Article and Full-Text PDF

Physician Perception of Disease Severity and Treatment Outcomes for Children and Adolescents with Atopic Dermatitis in Emerging Economies.

Dermatol Ther (Heidelb) 2022 Apr 26;12(4):999-1013. Epub 2022 Mar 26.

Fundacion Cidea, Paraguay, 2035, C1121ABE, Buenos Aires, Argentina.

Introduction: Pediatric atopic dermatitis (AD) leads to a considerable reduction in quality of life for patients and their families. Therapeutic options for pediatric patients with moderate-to-severe disease are limited and treatment is challenging. As little is understood about physician perceptions of pediatric AD in countries with emerging healthcare, we conducted a questionnaire-based study to identify treatment patterns and gaps. Read More

View Article and Full-Text PDF

Neuroimmune communication regulating pruritus in atopic dermatitis.

J Allergy Clin Immunol 2022 Jun 23;149(6):1875-1898. Epub 2022 Mar 23.

Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar. Electronic address:

Atopic dermatitis (AD) is a common, chronic-relapsing inflammatory skin disease with significant disease burden. Genetic and environmental trigger factors contribute to AD, activating 2 of our largest organs, the nervous system and the immune system. Dysregulation of neuroimmune circuits plays a key role in the pathophysiology of AD, causing inflammation, pruritus, pain, and barrier dysfunction. Read More

View Article and Full-Text PDF

Tralokinumab in Atopic Dermatitis: A Profile of Its Use.

Authors:
Hannah A Blair

Clin Drug Investig 2022 Apr 22;42(4):365-374. Epub 2022 Mar 22.

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Tralokinumab (tralokinumab-ldrm) [Adbry (USA); Adtralza (EU)], a human IgG4 monoclonal antibody that binds specifically to interleukin (IL)-13, is an effective and generally well tolerated treatment option for adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. In pivotal phase III trials, subcutaneous tralokinumab improved the clinical signs and symptoms of atopic dermatitis as well as quality of life (QOL). In ECZTRA 1 and 2, tralokinumab monotherapy was superior to placebo in the first 16 weeks of treatment, with improvements in pruritus and sleep scores seen as early as week 1. Read More

View Article and Full-Text PDF

Iron Deficiency and Pruritus: A Cross-Sectional Analysis to Assess Its Association and Relationship.

Indian J Dermatol 2021 Nov-Dec;66(6):705

Department of Skin and VD, Govt. Medical College, Kota, Rajasthan, India.

Background: As generalized pruritus can be a symptom of a systemic disease, iron deficiency may be the underlying internal cause of its symptoms. Because data on the relationship between iron deficiency and generalized chronic pruritus are limited, more research is needed to ensure proper diagnosis and management.

Aims: To evaluate the prevalence of iron deficiency in patients with generalized chronic pruritus in the southeast region of Rajasthan and to assess the correlation of serum ferritin with iron deficiency variables. Read More

View Article and Full-Text PDF

Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis.

Front Oncol 2022 25;12:732814. Epub 2022 Feb 25.

Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.

Background: Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment of patients with advanced tumors. However, little is known about their efficacy and safety in adjuvant settings after the resection of solid tumors.

Methods: We performed a meta-analysis on the efficacy and safety of programmed death 1 (PD1)/PD-1 ligand (PDL1) inhibitors in adjuvant therapy after tumor resection using Review Manager 5. Read More

View Article and Full-Text PDF
February 2022

Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.

Ann Med Surg (Lond) 2022 Mar 1;75:103420. Epub 2022 Mar 1.

Internal Medicine Consultant, Medical Specialties Department, King Fahad Medical City, Riyadh, Saudi Arabia.

Introduction And Importance: Messenger RNA vaccines, commonly known as mRNA vaccines, are the first COVID-19 vaccines that have been authorized and licensed in the United States. Two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) are available. Mass vaccination remains the most critical way to halt the spread of the COVID pandemic. Read More

View Article and Full-Text PDF

Multidisciplinary Management of Alagille Syndrome.

J Multidiscip Healthc 2022 23;15:353-364. Epub 2022 Feb 23.

Institute of Liver Disease & Transplantation, Dr Rela Institute & Medical centre, Bharath Institute of Higher Education and Research, Chennai, India.

Alagille syndrome (ALGS) is an autosomal dominant disorder characterized by involvement of various organ systems. It predominantly affects the liver, skeleton, heart, kidneys, eyes and major blood vessels. With myriads of presentations across different age groups, ALGS is usually suspected in infants presenting with high gamma glutamyl transpeptidase cholestasis and/or congenital heart disease. Read More

View Article and Full-Text PDF
February 2022

Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis.

J Dermatol Sci 2022 Feb 4;105(2):130-136. Epub 2022 Feb 4.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:

Background: There are limited data characterizing the association between renal disease and prurigo nodularis (PN).

Objective: To characterize the association and describe mechanistic disease linkages between PN and renal comorbidities.

Methods: We conducted a cross-sectional analysis of renal comorbidities in PN using TriNetX, a global health research network providing access to medical records. Read More

View Article and Full-Text PDF
February 2022

Calm before the Storm.

N Engl J Med 2022 Feb;386(5):479-485

From the Division of Gastroenterology and Hepatology (M.B.B.N., P.S.K.), the Division of Infectious Diseases (A.D.B.), and the Division of Hematology (S.A.P.), Department of Medicine, and the Department of Laboratory Medicine and Pathology (R.P.G.), Mayo Clinic, Rochester, MN.

View Article and Full-Text PDF
February 2022

Paediatric mycosis fungoides - characteristics, management and outcomes with particular focus on the folliculotropic variant.

J Eur Acad Dermatol Venereol 2022 May 2;36(5):671-679. Epub 2022 Mar 2.

Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.

Background: The literature on paediatric mycosis fungoides (MF) and especially its folliculotropic variant (FMF) is sparse.

Objectives: To describe the clinical manifestations, treatments, outcomes and long-term course of paediatric MF, including FMF.

Methods: A retrospective analysis was conducted of all consecutive MF patients diagnosed at ≤18 years attending two medical centres in 1995-2015. Read More

View Article and Full-Text PDF

Old and new therapeutic strategies in systemic sclerosis (Review).

Exp Ther Med 2022 Feb 13;23(2):134. Epub 2021 Dec 13.

Clinical Department, Faculty of Medicine and Pharmacy, 'Gr. T. Popa' University of Medicine and Pharmacy, 700115 Iași, Romania.

Systemic sclerosis (SSc) is a chronic inflammatory disease with autoimmune determinism having an incompletely known pathogenesis. Although not all links in the pathogenic chain are known, studies have shown that vasculopathy is the initial event and is followed by extensive fibrosis of the skin and internal organs. New therapeutic strategies have been developed in recent years, thanks to innovative research which has increased understanding of the disease mechanisms. Read More

View Article and Full-Text PDF
February 2022

Biological medication in atopic dermatitis.

Expert Opin Biol Ther 2022 05 13;22(5):643-649. Epub 2022 Jan 13.

Department of Dermatology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with intense itch/pruritus and skin lesions. Several modalities of treatment including topical therapy, systemic agents, and biologics are available for the treatment of disease. Despite this, management poses challenge due to chronic nature and recurrent episodes in many patients. Read More

View Article and Full-Text PDF